ALPCO  

Salem,  NH 
United States
http://www.alpco.com
  • Booth: 3467

Booth Profile

ALPCO offers a wide range of testing solutions, providing scientists and healthcare professionals with vital tools for advancing research and improving quality of care. Our gastroenterology product portfolio features colorimetric immunoassays to investigate inflammatory bowel disease, gut permeability disorders and pancreatic insufficiency including: calprotectin, zonulin and pancreatic elastase. Additionally, our therapeutic drug monitoring tools can assess response to biologics for IBD. Our flagship STELLUX® Chemiluminescent ELISA product line has recently expanded to include active GLP-1 (7-36) amide, and in the coming months we will be launching an FDA Class I Exempt Glucagon ELISA as well as an FDA Cleared Calprotectin ELISA.


 Press Releases

  • ALPCO, a leading producer of research and clinical immunoassays, announced it will feature its therapeutic drug monitoring (TDM) ELISA portfolio at the AACC’s 70th Clinical Lab Expo July 31-August 2 in Chicago. ALPCO’s TDM ELISA Portfolio can aid researching the immunogenicity of biologics commonly used to treat inflammatory bowel disease (IBD). The offering features ten colorimetric ELISAs that measure free drug level, free anti-drug antibodies (ADAs), and total anti-drug antibodies for IBD biologics including infliximab and adalimumab.

    “Although biologics have been used to treat IBD for many years, loss of response and primary non-response are still major issues which need to be better understood,” explains ALPCO’s president, Sean Conley. “Our TDM ELISAs allow researchers to confidently collect data in the context of these scenarios as they strive to develop methods for therapeutic drug monitoring to help personalize and improve IBD care.”

    ALPCO’s comprehensive TDM ELISA portfolio offers a more reliable method to investigate optimal concentrations of a given biologic, and immune responses to an IBD biologic, as well as understand if ADAs are playing a role in the lack of response to a given IBD biologic.  

    These assays are for research use only and not for use in diagnostic procedures in the United States. The Infliximab and Adalimumab Drug Level and Total ADA ELISAs, as well as the Infliximab Free ADA ELISA are Health Canada Licensed.

    Visit ALPCO in booth #3467 at the AACC’s 70th Clinical Lab Expo to learn more about the therapeutic drug monitoring ELISA portfolio.

    About ALPCO

    American Laboratory Products Company (ALPCO) was founded in 1991 as an importer and distributor of immunoassay-based products for the North American life science markets. The company has since grown into a premier channel representing over 60 collaborating partners from around the globe. Today, ALPCO offers a wide range of testing solutions, providing scientists and healthcare professionals with vital tools for advancing research and improving quality of care.

  • ALPCO, a leading producer of research and clinical immunoassays, provides an FDA Class I Exempt Pancreatic Elastase ELISA that can reliably measure PE-1 and, in turn, help laboratories save valuable resources. The company will promote the colorimetric ELISA at the AACC’s 70th Clinical Lab Expo in Chicago July 31 - August 2, 2018. The Pancreatic Elastase ELISA features superior specificity for measuring the PE-1 isoform which is found in stool and can be used to help define exocrine pancreatic function and diagnose pancreatic insufficiency.

    “Some pancreatic elastase assays on the market are not specific enough to the PE-1 isoform; while those that are specific to PE-1 are not cost effective,” explains ALPCO’s president, Sean Conley. “Our Pancreatic Elastase ELISA is an affordable solution to reliably measure PE-1 and better help those with pancreatic diseases, as it was designed with a monoclonal antibody system to enhance the specificity to PE-1.”

    Additionally, the Pancreatic Elastase ELISA is compatible with an Easy Stool Extraction Device which streamlines sample extraction and processing. The assay is also automatable, further enabling an increase in productivity and reduction in turnaround times.

    Visit ALPCO in booth #3467 at the AACC’s 70th Clinical Lab Expo to learn how the Pancreatic Elastase ELISA can help save laboratories time and resources.

    About ALPCO

    American Laboratory Products Company (ALPCO) was founded in 1991 as an importer and distributor of immunoassay-based products for the North American life science markets. The company has since grown into a premier channel representing over 60 collaborating partners from around the globe. Today, ALPCO offers a wide range of testing solutions, providing scientists and healthcare professionals with vital tools for advancing research and improving quality of care.

  • ALPCO, a leading producer of research and clinical immunoassays, will expand its STELLUX® Chemiluminescence platform into clinical gastroenterology testing, and plans to launch a chemiluminescence Calprotectin ELISA in 2019. The assay will feature increased sensitivity and the broadest range on the market to accurately quantify levels of calprotectin in human stool samples.

    A clinical trial is currently underway to evaluate the predictive values of the STELLUX® Chemiluminescence Calprotectin ELISA for the diagnosis of inflammatory bowel diseases (IBDs), specifically Crohn's disease (CD) and ulcerative colitis (UC). The clinical trial will evaluate the use of the assay to aid in the differentiation of IBD from irritable bowel syndrome (IBS) when used in conjunction with other diagnostic testing.

    “Our customers are experiencing many challenges with quantifying calprotectin levels,” explains ALPCO’s president, Sean Conley. “A large proportion of stool samples need to be rerun because the values fall above the measurable range, wasting valuable time while physicians and patients wait for results. We designed our STELLUX® Chemiluminescence Calprotectin ELISA to overcome this challenge to allow for a faster turnaround time of results for physicians and their patients.”

    Additionally, the STELLUX® Calprotectin ELISA is compatible with a stool extraction device which streamlines sample extraction and processing, saving laboratories time, money, and resources. The assay is also automatable, further enabling an increase in productivity and reduction in turnaround times.

    Visit ALPCO in booth #3467 at the AACC’s 70th Clinical Lab Expo to learn more about the upcoming STELLUX® Chemiluminescence Calprotectin ELISA and the STELLUX® Chemiluminescent ELISA Platform.

    About ALPCO

    American Laboratory Products Company (ALPCO) was founded in 1991 as an importer and distributor of immunoassay-based products for the North American life science markets. The company has since grown into a premier channel representing over 60 collaborating partners from around the globe. Today, ALPCO offers a wide range of testing solutions, providing scientists and healthcare professionals with vital tools for advancing research and improving quality of care.

  • ALPCO, a leading producer of research and clinical immunoassays, recently launched its new STELLUX® Chemi Active GLP-1 (7-36) amide ELISA . The chemiluminescence ELISA features increased sensitivity to accurately quantify active GLP-1 (7-36) amide levels as low as 1.5 pg/mL with a 25 µL sample volume. The low sample volume coupled with the increased sensitivity of the assay allows researchers to effectively quantify fasted levels of active GLP-1 (7-36) amide in rodents and humans.

    “Our customers were experiencing challenges in confidently quantifying active GLP-1 (7-36) amide levels without cross-reactivity, as well as being able to use the same kit in rodent and human models,” explains ALPCO’s president, Sean Conley. “We designed our ELISA to address these needs and provide a more sensitive and flexible tool to better serve a variety of model systems. We are confident these features will empower users to further their diabetes research beyond the bench and improve care.”

    Additionally, the STELLUX® Active GLP-1 (7-36) amide ELISA is highly specific with 100% cross-reactivity to GLP-1 (7-36) amide, and does not cross-react with glucagon and oxyntomodulin. The assay can be easily run in less than three hours, allowing users to run more samples each day. It is currently for research use only and not for use in diagnostic procedures.

    Visit ALPCO in Booth #3467 at the AACC’s Clinical Lab Expo to learn more about the STELLUX® Active GLP-1 (7-36) amide ELISA.

    About ALPCO

    American Laboratory Products Company (ALPCO) was founded in 1991 as an importer and distributor of immunoassay-based products for the North American life science markets. The company has since grown into a premier channel representing over 60 collaborating partners from around the globe. Today, ALPCO offers a wide range of testing solutions, providing scientists and healthcare professionals with vital tools for advancing research and improving quality of care.

  • ALPCO, a leading producer of research and clinical immunoassays, has announced the upcoming launch of its FDA Class I Exempt STELLUX® Chemi Glucagon ELISA. The chemiluminescence ELISA features increased sensitivity and a broad range to accurately quantify glucagon levels as low as 2.24 pmol/L and as high as 144 pmol/L. Glucagon measurements are used in the diagnosis and treatment of patients with various disorders of carbohydrate metabolism, including diabetes mellitus, hypoglycemia, and hyperglycemia.

    “Our customers were experiencing challenges in confidently quantifying glucagon levels without cross reactivity to oxyntomodulin, a proglucagon peptide containing the glucagon sequence known for interfering with glucagon assays,” explains ALPCO’s president, Sean Conley. “We designed our STELLUX® Chemi Glucagon ELISA to address this need and provide a more sensitive, specific multifunctional diagnostic and research tool to laboratories. We are confident these features will empower users to both further their research and improve clinical outcomes.”

    The STELLUX® Chemi Glucagon ELISA is highly specific with 100% cross-reactivity to glucagon, and does not cross-react with other proglucagon peptides such as oxyntomodulin, glicentin and gastric inhibitory polypeptide. The broad range and increased sensitivity of the assay allows laboratories to effectively quantify both fasted and fed levels of glucagon in mouse, rat, and human plasma sample. Additionally, the assay is validated for use with cell culture and is a robust tool for perifusion models.

    Visit ALPCO in booth 3467 at the AACC’s 70th Annual Clinical Lab to learn more about the STELLUX® Glucagon ELISA.

    About ALPCO

    American Laboratory Products Company (ALPCO) was founded in 1991 as an importer and distributor of immunoassay-based products for the North American life science markets. The company has since grown into a premier channel representing over 60 collaborating partners from around the globe. Today, ALPCO offers a wide range of testing solutions, providing scientists and healthcare professionals with vital tools for advancing research and improving quality of care.


 Additional Info

Included in the Export Interest Directory?
Yes
Business Needs:
Distributor/Agent/Representative
Products to be exported:
Immunoassays and ELISA kits